Results 161 to 170 of about 10,309 (205)
Lost Rate Control and Tachycardia-Induced Cardiomyopathy as a Result of an Interaction Between Enzalutamide and Diltiazem. [PDF]
JACC Case Repde Boer A, Koshman S, Gyenes G.
europepmc +1 more source
Pulmonary Rehabilitation in Primary Care: Functional and Emotional Impact in a Patient with COPD: A Case Report. [PDF]
Reports (MDPI)Esteves V, Gonçalves SD.
europepmc +1 more source
A very rare cause of oliguric acute kidney disease: crescentic C3 glomerulopathy. [PDF]
Oxf Med Case ReportsKaynar K +4 more
europepmc +1 more source
Combination blood pressure lowering therapy in patients with type 2 diabetes: messages from the ADVANCE trial. [PDF]
J HypertensWang N +9 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Opinion on Pharmacotherapy, 2005
Perindopril is a third-generation ACE inhibitor that is characterised as a small, lipophilic molecule with a therapeutically active carboxyl side group. These and other features combine to make this a unique member of a very well-established class of drugs that have proven efficacy in a wide range of cardiovascular diseases.
K, Alfakih, A S, Hall
+5 more sources
Perindopril is a third-generation ACE inhibitor that is characterised as a small, lipophilic molecule with a therapeutically active carboxyl side group. These and other features combine to make this a unique member of a very well-established class of drugs that have proven efficacy in a wide range of cardiovascular diseases.
K, Alfakih, A S, Hall
+5 more sources
Drugs, 2002
Perindopril is a long-acting ACE inhibitor, acting through its only active metabolite perindoprilat. It inhibits the renin-angiotensin system by preventing both the conversion of angiotensin I to angiotensin II and the degradation of bradykinin, thereby reducing the vasoconstriction and left ventricular remodelling characteristic of heart failure ...
Dene, Simpson +2 more
+5 more sources
Perindopril is a long-acting ACE inhibitor, acting through its only active metabolite perindoprilat. It inhibits the renin-angiotensin system by preventing both the conversion of angiotensin I to angiotensin II and the degradation of bradykinin, thereby reducing the vasoconstriction and left ventricular remodelling characteristic of heart failure ...
Dene, Simpson +2 more
+5 more sources
Heart disease (Hagerstown, Md.), 2001
Perindopril is the newest angiotensin-converting enzyme inhibitor to be approved in the United States. It is indicated for the treatment of essential hypertension either alone or in combination with other antihypertensives, especially thiazide diuretics. Perindopril must be converted to perindoprilat, its active metabolite.
D C, O'Loughlin, V L, Chu, D, Singh
openaire +1 more source
Perindopril is the newest angiotensin-converting enzyme inhibitor to be approved in the United States. It is indicated for the treatment of essential hypertension either alone or in combination with other antihypertensives, especially thiazide diuretics. Perindopril must be converted to perindoprilat, its active metabolite.
D C, O'Loughlin, V L, Chu, D, Singh
openaire +1 more source